PubRank

David B Clifford

Author PubWeight™ 117.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2010 7.56
2 Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006 5.20
3 Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004 4.64
4 Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2005 3.47
5 PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013 3.02
6 HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012 2.95
7 Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010 2.91
8 Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009 2.88
9 Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010 2.48
10 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005 2.43
11 Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011 2.19
12 Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011 1.90
13 Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 2011 1.85
14 Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry 2010 1.73
15 The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003 1.70
16 HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009 1.64
17 Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009 1.63
18 Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol 2011 1.57
19 Clinical validation of the NeuroScreen. J Neurovirol 2005 1.57
20 Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011 1.53
21 Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012 1.52
22 Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 2007 1.52
23 Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009 1.45
24 Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005 1.39
25 Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 1.36
26 Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 2005 1.32
27 HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One 2013 1.27
28 Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011 1.26
29 Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 2010 1.19
30 Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003 1.16
31 Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr 2011 1.16
32 JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011 1.13
33 Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008 1.08
34 Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis 2013 1.05
35 HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep 2008 1.04
36 Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia 2012 1.04
37 Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006 1.03
38 HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity. Nat Clin Pract Neurol 2007 1.03
39 Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics 2006 1.03
40 Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care 2011 1.01
41 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 2012 1.00
42 African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis 2010 0.99
43 A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One 2007 0.97
44 Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav 2011 0.96
45 The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol 2013 0.96
46 Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 2012 0.95
47 Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol 2011 0.95
48 Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009 0.95
49 Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007 0.94
50 Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr 2013 0.93
51 Global NeuroAIDS roundtable. J Neurovirol 2013 0.92
52 The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007 0.91
53 Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology 2012 0.91
54 Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 2013 0.91
55 Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother 2012 0.90
56 Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials 2007 0.89
57 Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics 2012 0.89
58 Atypical PML leading to a diagnosis of common variable immunodeficiency. Neurology 2005 0.87
59 HIV peripheral neuropathy progression: protection with glucose-lowering drugs? J Neurovirol 2012 0.86
60 Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol 2012 0.85
61 Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol 2012 0.85
62 Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. Mult Scler 2010 0.85
63 Simplification of the research diagnosis of HIV-associated sensory neuropathy. HIV Clin Trials 2009 0.84
64 Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother 2012 0.84
65 Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere. Neurology 2012 0.83
66 Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr 2006 0.82
67 Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol 2013 0.81
68 Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology 2012 0.81
69 Therapeutic conundrum: AIDS therapies may be double-edged swords. Neurology 2010 0.81
70 Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. J Neuropsychiatry Clin Neurosci 2011 0.81
71 The manifold faces of PML and the challenge of diagnosis. Neurology 2011 0.79
72 The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol 2014 0.79
73 Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS 2012 0.77
74 Histoplasmoma: isolated central nervous system infection with Histoplasma capsulatum in a patient with AIDS. Case report and brief review of the literature. Clin Neurol Neurosurg 2006 0.77
75 Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 2014 0.77
76 Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2010 0.76
77 Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res 2016 0.76
78 Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211. HIV Clin Trials 2010 0.76
79 Viral escape in cerebrospinal fluid--an achilles heel of HIV therapy? J Infect Dis 2010 0.75
80 Time is brain for infections too? Neurology 2011 0.75
81 The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 2016 0.75
82 Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals. J Acquir Immune Defic Syndr 2014 0.75
83 Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med 2013 0.75
84 Tumefactive demyelination in a patient with human immunodeficiency virus. J Neurovirol 2013 0.75
85 Susac syndrome in a patient with human immunodeficiency virus infection. J Neurovirol 2013 0.75
86 Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain 2015 0.75
87 Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen. J Neurovirol 2015 0.75
88 Lessons from the clinic: a case of natalizumab-associated PML. Neurology 2011 0.75
89 2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment. J Neurovirol 2015 0.75
90 Part 2: history of 20th century neurology: decade by decade. Ann Neurol 2003 0.75